Eliem Therapeutics, following the close of the acquisition of Tenet Medicines will be focused on developing therapeutics for autoimmune-driven inflammatory diseases, including advancing TNT119, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy.

Sign Up For Email Alerts

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

More Information
More Information